EDSA · Edesa Biotech, Inc. · Insider Trading

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

On June 16, 2026, the Reporting Person purchased in a private placement, 153,550 shares of the Issuer's common shares, at a purchase price of $5.21 per share, for an aggregate purchase price of $799,995.50.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2025.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 166,287 shares shall vest monthly in equal proportions over twelve (12) months, commencing on the grant date and (ii) 96,913 shares shall vest in equal proportions over thirty-six (36) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 142,592 shares shall vest in equal proportions over eighteen (18) months, commencing on the grant date and (ii) 64,609 shares vest in equal proportions over thirty-six (36) months, commencing on the grant date.

Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023.

Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

On February 11, 2025, the Reporting Person purchased in a private placement, 100 shares of the Issuer's newly designated Series B-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share for an aggregate purchase price of $1.0 million. The Preferred Shares are immediately convertible at $1.92 per share, to the extent that after giving effect to such conversion the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer.

The Preferred Shares are perpetual and therefore have no expiration date.

Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus all other amounts due in respect of such Preferred Share (excluding distributions), by the conversion price at the time of conversion.